Arcus Biosciences Inc
RCUS.N- Latest Trade
- trading higher27.33USD
- Change
- 0
- % Change
0.00%
- As of Aug 8 2022. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- 16.75 - 49.09
- Previous Close
- 27.33
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 21.45
- Shares Out (Mil)
- 72.09
- Market Cap
- 1,972.13
- Forward P/E
- -6.85
- Dividend Yield
- -99,999.99
Key Statistics
1.72727273 mean rating - 11 analysts
- P/E Excl. Extra Items (TTM)
- 185.10
- Price To Sales (TTM)
- 4.83
- Price To Book (Quarterly)
- 2.64
- Price To Cash Flow (Per Share TTM)
- 27.41
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- 6.42
- Return On Equity (TTM)
- 5.62
2021 (millions USD)
About Arcus Biosciences Inc (RCUS.N)
Company Information
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on developing cancer therapies. The Company's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The Company's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.
Address
3928 Point Eden WayHAYWARD, CA
94545-3719
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Terry J. Rosen
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Juan Carlos Jaen
- President, Co-Founder, Director
- Robert C. Goeltz
- Chief Financial Officer, Principal Financial and Accounting Officer
- Jennifer A Jarrett
- Chief Operating Officer, Director
- Carolyn Tang
- General Counsel
- Yasunori Kaneko
- Lead Independent Director
- Linda Higgins
- Director
- Merdad V. Parsey
- Director
- Kathryn E. Falberg
- Independent Director
- David L. Lacey
- Independent Director
- Nicole Lambert
- Independent Director
- Patrick Machado
- Independent Director
- Andrew Perlman
- Independent Director
- Antoni Ribas
- Independent Director
Latest News
- MarketsU.S. RESEARCH ROUNDUP Datadog, Home Depot, Walmart
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Home Depot and Walmart, on Friday.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,780.30 | 0.42%Positive |
| Copper | 657.50 | 0.25%Positive |
| Brent Crude Oil | 94.57 | 0.37%Negative |
| CBOT Soybeans | 1,603.75 | 0.68%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,145.19 | -- |
| Euro STOXX 50 | 3,767.55 | 1.13%Positive |
| FTSE 100 | 7,504.61 | 0.87%Positive |
| Nikkei 225 | 28,249.24 | 0.26%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes